Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 24th. The stock was bought at an average cost of $5.70 per share, with a total value of $85,500.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $17,493,020.70. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, August 17th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average cost of $5.54 per share, with a total value of $55,400.00.
  • On Monday, August 13th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was bought at an average cost of $5.33 per share, with a total value of $79,950.00.
  • On Thursday, August 9th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average cost of $5.45 per share, with a total value of $54,500.00.
  • On Thursday, July 26th, Phillip Md Et Al Frost acquired 90,000 shares of Opko Health stock. The stock was bought at an average cost of $5.06 per share, with a total value of $455,400.00.
  • On Tuesday, July 24th, Phillip Md Et Al Frost acquired 55,000 shares of Opko Health stock. The stock was bought at an average cost of $5.60 per share, with a total value of $308,000.00.
  • On Friday, July 20th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average cost of $5.89 per share, with a total value of $58,900.00.
  • On Wednesday, July 18th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average cost of $6.05 per share, with a total value of $60,500.00.
  • On Monday, July 16th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was bought at an average cost of $5.68 per share, with a total value of $85,200.00.
  • On Tuesday, July 3rd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was bought at an average cost of $4.75 per share, with a total value of $47,500.00.
  • On Friday, June 29th, Phillip Md Et Al Frost acquired 7,720 shares of Opko Health stock. The stock was bought at an average cost of $4.71 per share, with a total value of $36,361.20.

OPK opened at $5.79 on Wednesday. Opko Health Inc. has a 12-month low of $2.66 and a 12-month high of $7.24. The company has a quick ratio of 0.90, a current ratio of 1.05 and a debt-to-equity ratio of 0.03. The company has a market cap of $3.15 billion, a price-to-earnings ratio of -19.97 and a beta of 1.81.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. The company had revenue of $263.69 million during the quarter, compared to analyst estimates of $260.37 million. analysts expect that Opko Health Inc. will post -0.23 EPS for the current year.

A number of equities analysts have issued reports on the stock. BidaskClub raised shares of Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 price target on shares of Opko Health in a research report on Tuesday, August 7th. Finally, ValuEngine raised shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $10.95.

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Opko Health during the 2nd quarter worth approximately $136,000. North Star Investment Management Corp. purchased a new position in shares of Opko Health during the 2nd quarter valued at approximately $141,000. RPg Family Wealth Advisory LLC increased its holdings in shares of Opko Health by 74.3% during the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 13,250 shares in the last quarter. Castleview Partners LLC purchased a new position in shares of Opko Health during the 1st quarter valued at approximately $103,000. Finally, Xact Kapitalforvaltning AB increased its holdings in shares of Opko Health by 58.2% during the 1st quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 21,300 shares in the last quarter. 24.81% of the stock is owned by institutional investors.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Story: Fiduciary

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.